Compare PED & OLMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PED | OLMA |
|---|---|---|
| Founded | N/A | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.4M | 2.6B |
| IPO Year | N/A | 2020 |
| Metric | PED | OLMA |
|---|---|---|
| Price | $0.54 | $27.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $1.50 | ★ $40.50 |
| AVG Volume (30 Days) | 184.3K | ★ 3.8M |
| Earning Date | 11-17-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 156.43 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $33,244,999.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $305.89 | N/A |
| P/E Ratio | $5.21 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.43 | $2.86 |
| 52 Week High | $1.00 | $36.26 |
| Indicator | PED | OLMA |
|---|---|---|
| Relative Strength Index (RSI) | 47.91 | 56.10 |
| Support Level | $0.50 | $25.62 |
| Resistance Level | $0.58 | $36.26 |
| Average True Range (ATR) | 0.04 | 2.72 |
| MACD | 0.00 | -0.55 |
| Stochastic Oscillator | 45.07 | 21.38 |
PEDEVCO Corp is an oil and gas company focused on oil and natural gas development, exploration, and production. The company focuses on legacy properties where there is a long production history, well-defined geology and existing infrastructure that can be leveraged when applying modern field management technologies. The current properties of the company are located in the San Andres formation of the Permian Basin, situated in West Texas and eastern New Mexico (the Permian Basin), and in the Denver-Julesberg Basin (D-J Basin) in Colorado and Wyoming.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.